KRTAP10-8: A Potential Drug Target and Biomarker (G386681)

Target Name: KRTAP10-8

NCBI ID: G386681

KRTAP10-8

KRTAP10-8: A Potential Drug Target and Biomarker

KRTAP10-8 (KAP18-8), a gene expressed in the brain, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. The gene is located on chromosome 18 and encodes for the KRTAP10 protein, which is a known protein involved in synaptic transmission and neurotransmitter release. The discovery of KRTAP10-8 as a potential drug target and biomarker has significant implications for the development of new treatments for psychiatric and neurological disorders.

KRTAP10-8 is expressed in various tissues and cell types, including the brain, where it is involved in the regulation of neuronal excitability and synaptic plasticity. The protein has been shown to play a role in the transmission of signals in the brain, which is critical for the development and progression of various psychiatric and neurological disorders.

Research has suggested that disruptions in KRTAP10-8 expression may contribute to the development of these disorders. For example, studies have shown that individuals with certain genetic variations in the KRTAP10 gene are at increased risk for developing symptoms of depression and anxiety. Additionally, alterations in KRTAP10-8 expression have been implicated in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Given the potential role of KRTAP10-8 in the development and progression of psychiatric and neurological disorders, it is an attractive target for drug development. Studies have shown that inhibitors of KRTAP10-8 have the potential to treat various psychiatric and neurological disorders, including depression, anxiety, and neurodegenerative diseases.

In addition to its potential as a drug target, KRTAP10-8 has also been identified as a potential biomarker for psychiatric and neurological disorders. The protein is expressed in various tissues and cell types, including the brain, and has been shown to play a role in the regulation of neuronal excitability and synaptic plasticity. Therefore, KRTAP10-8 may be a useful biomarker for the diagnosis and monitoring of these disorders.

The identification of KRTAP10-8 as a potential drug target and biomarker has significant implications for the development of new treatments for psychiatric and neurological disorders. Further research is needed to fully understand the role of KRTAP10-8 in the development and progression of these disorders, as well as the development of new treatments.

In conclusion, KRTAP10-8 is a gene expressed in the brain that has been identified as a potential drug target and biomarker for various psychiatric and neurological disorders. The discovery of KRTAP10-8 has significant implications for the development of new treatments for these disorders and has the potential to revolutionize our understanding of these conditions. Further research is needed to fully understand the role of KRTAP10-8 in the development and progression of these disorders, as well as the development of new treatments.

Protein Name: Keratin Associated Protein 10-8

Functions: In the hair cortex, hair keratin intermediate filaments are embedded in an interfilamentous matrix, consisting of hair keratin-associated proteins (KRTAP), which are essential for the formation of a rigid and resistant hair shaft through their extensive disulfide bond cross-linking with abundant cysteine residues of hair keratins. The matrix proteins include the high-sulfur and high-glycine-tyrosine keratins

The "KRTAP10-8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KRTAP10-8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets